Form 4: Apogee Therapeutics Director Mark McKenna Granted Stock Options

Apogee Therapeutics, Inc. Director Mark C. McKenna was granted 14,461 stock options with an exercise price of $41.66, vesting on the one-year anniversary of the grant date.

Summary

• Mark C. McKenna, a Director of Apogee Therapeutics, Inc. (APGE), was granted 14,461 stock options.
• The stock options have an exercise price of $41.66 per share.
• These options will vest on June 17, 2026, which is the one-year anniversary of the grant date (June 17, 2025).
• Vesting is contingent upon Mr. McKenna's continued service to Apogee Therapeutics, Inc. on the vesting date.
• The options have an expiration date of June 17, 2035.
• Following this transaction, Mr. McKenna beneficially owns 14,461 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard practice that aligns the director's interests with those of the shareholders, indicating continued commitment to the company's long-term performance. This is generally viewed as a positive for corporate governance and incentive alignment.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance and shareholder value of Apogee Therapeutics, Inc.

Future Outlook

The stock options granted to Director Mark C. McKenna are forward-looking, with a vesting date one year from the grant date and an expiration date ten years from the grant date, indicating a long-term incentive structure.

Industry Context

The grant of stock options to board members is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of director compensation to incentivize long-term performance and align interests with shareholders.

Related Party Transactions

• The grant of stock options to Director Mark C. McKenna can be considered a related party transaction as it involves compensation to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the director's interests with shareholder value through equity ownership and long-term incentives.

Next Steps

• Vesting of 14,461 stock options on June 17, 2026, subject to Mark C. McKenna's continued service to Apogee Therapeutics, Inc.

Key Dates

Keywords

Apogee Therapeutics, APGE, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, SEC Filing, Mark McKenna